This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu
Trial record 3 of 3 for:    NM101

A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04669028
Recruitment Status : Completed
First Posted : December 16, 2020
Last Update Posted : November 21, 2023
Information provided by (Responsible Party):
BioVie Inc.

Brief Summary:
U.S. multicenter, parallel group study designed to evaluate the safety and efficacy of oral 20 mg twice daily (BID) NE3107 vs placebo in 400 adult subjects with mild to moderate probable AD. Dual co-primary endpoints (Clinical Dementia Rating Scale Sum of Boxes, CDR-SB and ADAS-Cog12) will be evaluated as the change from Baseline to Week 30. Secondary endpoints include measures of cognition, neuropsychological deficits, functional performance, and glycemic control. A subset of patients may volunteer for exploratory magnetic resonance imaging (volumetric changes) and positron emission tomography (cortical glucose metabolic rate) scans at baseline and week 30.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: NE3107 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 439 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease
Actual Study Start Date : August 5, 2021
Actual Primary Completion Date : September 30, 2023
Actual Study Completion Date : October 25, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NE3107
Hard gelatin capsule containing 20 mg micronized NE3107 drug substance blended with common excipients for oral formulations
Drug: NE3107
NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.

Placebo Comparator: placebo
Hard gelatin capsule containing only common excipients for oral formulations
Drug: Placebo
capsules that do not contain NE3107

Primary Outcome Measures :
  1. Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) [ Time Frame: baseline and week 30 (end of study) ]
    test of 6 cognitive or functional domains, including memory, orientation, judgment, community affairs, home hobbies, and personal care are scored by certified raters after interviewing both participants and their informants. Higher score is indicative of more severe disease. The minimum score is 0 and the maximum score is 18. The CDR-SB is a co-primary outcome with ADAS-Cog12

  2. Change in Alzheimer's Disease Assessment Scale Cognitive Subscale 12 [ADAS Cog12] [ Time Frame: baseline and week 30 (end of study) ]
    The ADAS-Cog was developed to assess the level of cognitive dysfunction in Alzheimer's disease. It is also used in studies of interventions in people with mild cognitive impairment. It is also used for assessing the efficacy of antidementia treatments. The test is administered and scored by a certified rater to assess the cognitive domains of memory, language, orientation and praxis. A higher score is indicative of more severe disease, with 0 (no cognitive deficit) being the lowest score possible and 80 being the highest score and associated with severe cognitive impairment. ADAS-Cog12 is a co-primary outcome with CDR-SB.

Secondary Outcome Measures :
  1. Alzheimer's Disease clinical COMposite Score (ADCOMS) [ Time Frame: baseline and week 30 (end of study) ]
    composite score of questions from different cognitive tests (CDR, MMSE, and ADAS-Cog12). total score ranges from 0-1.97, with higher scores indicating worse disease

  2. Alzheimer's Disease Cooperative Study Activities of Daily Living Scale [ Time Frame: baseline and week 30 (end of study) ]
    23 item scale with total score of 0-78, with a lower score indicating worse disease

  3. Mini Mental State Exam (MMSE) [ Time Frame: baseline and week 30 (end of study) ]
    30 questions with a total score of 0-30, with a lower score indicating worse disease

  4. Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS CGIC] [ Time Frame: baseline and week 30 (end of study) ]
    The ADCS-CGIC focuses on clinicians' observations of change in the subject's cognitive, functional, and behavioral performance since the beginning of a trial. It relies on both direct examination of the subject and interview of informants (e.g. trial partner). global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change.

  5. Neuropsychiatric Index 12 [ Time Frame: baseline and week 30 (end of study) ]
    12 questions with total score 0-12, with higher score indicating worse disease

  6. CDR Global Score [ Time Frame: baseline and week 30 (end of study) ]
    The CDR is a 5-point scale used to characterize 6 domains of cognitive and functional performance applicable to AD and related dementias. Higher score is more severe disease symptoms. The overall CDR Global Score is calculated through the use of an algorithm. 0= normal, 0.5= very mild dementia, 1=mild dementia, 2=moderate dementia, 3=severe dementia

Other Outcome Measures:
  1. Resource Utilization in Dementia (short version, Lite) [ Time Frame: baseline and week 30 (end of study) ]
    compiles data on the use of social services, frequency and duration of hospitalizations, unscheduled contacts with health care professionals, use of concomitant medications by both the caregiver and the patient, amount of time the caregiver spends caring for the patient and missing work, and patients' use of study medication.

  2. volumetric magnetic resonance imaging (vMRI) [ Time Frame: baseline and week 30 (end of study) ]
  3. cortical metabolic rate using fluorodeoxyglucose positron emission [ Time Frame: baseline and week 30 (end of study) ]
  4. fasting blood glucose [ Time Frame: baseline and week 30 (end of study) ]
    measures glucose concentration in blood after overnight fasting

  5. postprandial glucose excursions [ Time Frame: baseline and week 30 (end of study) ]
    3-day average of postprandial glucose measure by continuous glucose monitoring

  6. Homeostatic assessment of insulin resistance 2 (HOMA2-IR) [ Time Frame: baseline and week 30 (end of study) ]
    blood tests for insulin and glucose levels

  7. C-reactive protein [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  8. plasma ratio of amyloid beta 1-42/1-40 [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  9. plasma concentration of phospho-tau 217 [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  10. plasma concentration of glial fibrillary acidic protein [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  11. plasma concentration of Neurofilament light (NfL) [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  12. change in DNA methylation of genes associated with measures of biological age [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  13. change concentration of serum leptin [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  14. change in concentration of serum adiponectin [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  15. change in plasma concentration of tumor necrosis factor (TNF) [ Time Frame: baseline and week 30 (end of study) ]
    blood test

  16. change in plasma concentration of monocyte chemoattractant protein (MCP1) [ Time Frame: baseline and week 30 (end of study) ]
    blood test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Male or female subject aged 60 to 85 y at Screening (V1). 2. Has mild to moderate probable AD as defined by all of the following criteria:

    1. Meets the National Institute on Aging and Alzheimer's Association (NIA-AA, 2011) criteria of all cause dementia and probable AD.
    2. Has a Clinical Dementia Rating (CDR) (Section 8.1.6) Standard Global Score of 1 to 2, inclusive (mild to moderate).
    3. Has a MMSE score of ≥14 and ≤24 at both Screening and Baseline visits. The difference in scores between Screening and Baseline must be < 3 points (i.e., the difference must not exceed 3 points). (Section 8.1.5)
    4. Has an historical MRI or CT scan of the brain on file no earlier than AD diagnosis that fails to exhibit features of another potential pathobiology that could better account for the cognitive disorder.

      3. Historical evidence of impairment on a mental status exam or documented prior diagnosis of or treatment for dementia from a health care professional.

      4. Has a modified Hachinski Ischemic Scale (Section 8.1.8) score of ≤4 at Screening (V1).

      5. If taking an anticholinesterase inhibitor (AChEI) (e.g., donepezil, galantamine, rivastigmine) and/or memantine at Screening (V1):

    1. Must have been taking the medication(s) for ≥3 mo, and
    2. Current dose regimen and form must have remained stable for ≥6 wk and must remain stable throughout participation in the study.

      NOTE: Subjects not being treated with an AChEI and/or memantine at Screening (V1) may also be enrolled if initiation of an AChEI and/or memantine is not planned for the time period during which the subject will be participating in this study.

      NOTE: Dosage changes during the study due to clinical deterioration should be discussed with the Medical Monitor prior to being implemented.

      6. If taking medications for glycemic control at the time of Screening (V1), must be stable on the current dose regimen and form for ≥3 mo prior to randomization and must remain stable throughout participation in the study.

      7. Females taking hormone replacement therapy (HRT) must have maintained a stable regimen for at least two years prior to randomization and agree to continue the regimen until completing the final safety assessment in Week 30 at the end of the study.

      8. Must meet one of the following criteria:

    1. Females: Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 mo prior to Screening (V1) or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 y; if needed, the Investigator may confirm menopausal status through an FSH assessment at Screening [V1]). 6.8.1
    2. Males: Vasectomized. If not vasectomized, must use an appropriate contraception method as noted in Section 6.8.1.

      9. Must provide voluntary written informed consent prior to Screening (V1). If the subject is unable to provide informed consent due to cognitive status, the subject must provide assent and a legally authorized representative provides full written informed consent on behalf of the subject.

      10. Willing to allow collection of blood for ApoE genotyping. 11. Able to comply with the study procedures, in the opinion of the Investigator.

      12. Has a primary caregiver/study partner willing to accept responsibility for supervising the treatment (e.g., administering study drug), accompanying the subject to clinic visits and assessing the condition of the subject throughout the study in accordance with all protocol requirements. The primary caregiver/study partner must be willing to sign the caregiver ICF.

      Exclusion Criteria:

  • 1. Has prior brain imaging inconsistent with probable AD 2. A history of a stroke that resulted in a cognitive or motor deficit or, MRI or CT evidence of a moderate or large cerebral infarct.

    1. Should there be any evidence of neurologic symptoms between the date of the scan confirming diagnosis and Screening (V1), rescanning is necessary.

      3. Has clinically relevant abnormal laboratory tests including serum vitamin B12 deficiency, thyroid function abnormality, severe anemia, or electrolyte abnormality.

      4. Diagnosis of type 1 diabetes or type 2 diabetes requiring insulin treatment or the need to use continuous glucose monitoring. Subjects who become insulin dependent during the study may not continue to participate in the study.

      5. History of epilepsy or seizure disorder requiring ongoing treatment, or any seizure or loss of consciousness within 12 mo prior to Screening (V1).

      6. Subjects are ineligible, if in the opinion of the investigator, they have deficits in speech, comprehension, auditory functioning, or vision which would adversely impact their ability to perform the study's cognitive test procedures, complete rating scales, or engage in interviews.

      7. Has any of the following laboratory findings at Screening (V1):

    1. Alanine aminotransferase >3 × upper limit of normal (ULN), aspartate aminotransferase >3 × ULN, or history of clinically significant liver disease in the Investigator's medical judgment.
    2. Hemoglobin ≤10 g/dL.
    3. International normalized ratio >1.5 if not on anticoagulant medication; if the subject is on anticoagulant medication, the anticoagulant medication should be optimized and on a stable dose for ≥4 wk prior to Screening (V1).
    4. Creatinine clearance (Cockcroft Gault formula) of <45 mL/min.
    5. Known to be seropositive for human immunodeficiency virus (1 and 2), hepatitis B, or hepatitis C. Subjects with hepatitis C who had spontaneous resolution or received successful curative treatment (e.g., HARVONI® [ledipasvir/sofosbuvir]) with a documentation of undetectable viral load for at least 3 mo may be allowed. Serological testing will not be performed as part of this study.

      8. Female subjects with child-bearing potential (premenopausal, menstrual bleeding within the last 12 months) or who are pregnant or breastfeeding.

      9. History of any medical illness such as cancer requiring systemic therapy in the last 5 y, except for localized basal cell carcinoma of the skin, in situ cervical cancer successfully treated with surgical excision, and stable (for ≥90 d prior to Screening [V1]) prostate cancer.

      10. History of breast cancer. 11. History of severe heart failure (Grade 2 or higher on the New York Heart Association scale), major stroke, uncontrolled seizure disorder, or other medical illness that, in the Investigator's opinion, will increase the subject's risk of participation in the study or confound study assessments.

      12. Any surgery requiring general anesthesia that is planned to occur during the study. Local anesthesia during outpatient surgery is permitted if, in the opinion of the Investigator, the operation will not interfere with study procedures and subject safety.

      13. History or current evidence of major psychiatric illness such as schizophrenia, bipolar disorder, or major depressive disorder that may interfere with the subject's ability to perform the study and all assessments.

    1. Geriatric Depression Scale Short Form (GDS SF) score >8 at Screening (V1). NOTE: Mild depression or depressive mood arising in the context of AD are not criteria for exclusion. The use of anti epileptic medication for non-seizure-related treatment or the use of antidepressants is allowed if the dose has remained stable for ≥60 d prior Screening (V1).

      14. Violent or aggressive behavior that may interfere with study participation 15. History of active suicidal thoughts (Type 4 or 5 on the C SSRS) in the 6 mo prior to Screening (V1) or at Baseline (V2), history of a suicide attempt in the previous 2 y or >1 lifetime suicide attempt, or are at serious suicide risk, in the Investigator's clinical judgment.

      16. History of alcohol or drug abuse or dependence within 24 mo of Screening (V1) as defined by the Diagnostic and Statistical Manual of Mental Disorders 5.

    1. Positive urine screen for drugs of abuse that include methadone, cocaine, and amphetamines; positive urine screen for opiates, barbiturates, or benzodiazepines without a prescription.

      17. Has participated in another Investigational New Drug research study involving small molecule drugs within 60 d or biological drugs within 90 d prior to the first dose of study drug in this study (Baseline [V2]) or within 5 half-lives of the other investigational medicinal product, whichever is longer.

      18. History of Covid-19 (SARS-CoV-2) infection within 6-weeks prior to screening. Subjects with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19, that may affect participant safety or interfere with efficacy assessments, based on the Investigator's clinical judgment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04669028

Layout table for location information
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43221
Sponsors and Collaborators
BioVie Inc.
Layout table for additonal information
Responsible Party: BioVie Inc. Identifier: NCT04669028    
Other Study ID Numbers: NM101
First Posted: December 16, 2020    Key Record Dates
Last Update Posted: November 21, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders